{Title}

Bio€quity Europe | 2019

20th Annual Bio€quity Europe



May 20 - 21, 2019 | Barcelona

 
LOCATION

Barcelona Travel & Hotel Information

Crowne Plaza Barcelona Fira Center
Avenida Rius I Taulet, 1-3
Barcelona, Spain

 


The 20th Bio€quity Europe : Hot Topics, Hot Spots

Biotech is entering a golden age. The world is seeing a flood of new therapies that have long been the promise of this industry.

Gene Therapies.  Stem Cell Treatments.  Antisense.  siRNA.  CAR T.

Is Europe playing its part?

Are they holding their own in inventing the next-generation of therapies and technologies?

And is Europe creating hot beds of innovation to lead the way forward?

For 20 years, Bio€quity Europe has been holding up a mirror to reflect Europe’s progress in the biotech revolution.

Today, even more exciting science and technologies are on the horizon. But the momentum is global. Europe must keep pace to attract the best talent and investment, create jobs and improve public health.

In 2019, Bio€quity Europe gathers European “Hot Topics” companies and their investors to measure their progress and debate the path forward.

For 20 years, Bio€quity Europe has showcased more than 800 leading European companies to thousands of investment and pharma business development professionals. Delegates from 24 nations attended Bio€quity Europe last year in Ghent.

Presenting Company slots running out. Click here to nominate your company.


Return to Conferences List
SCHEDULE
Sunday, May 19, 2019

19:00  to  21:00
Bio€quity Europe Registration Open
Crowne Plaza Barcelona Fira Center - level 0
Welcome Reception
Crowne Plaza Barcelona Fira Center - Terraza Montjuic
Bio€quity Europe Welcome Reception - Hosted By: BioCentury, EBD Group, Kurma Partners and Seroba Life Sciences

Monday, May 20, 2019

07:45  to  18:00
Registration Open
Crowne Plaza Barcelona Fira Center - level 0
09:00  to  09:25
Offical Greetings from the Hosts
Room - Rubí + Zafir (level -1)
09:25  to  09:30
Euronext Opening Bell Ceremony
Room - Rubí + Zafir (level -1)
09:30  to  10:15
Opening Plenary Session
Room - Rubí + Zafir (level -1)
Hot Topics, Hot Spots
Biotech is entering a golden age. Gene therapies. Stem cell treatments. Antisense. siRNA. CAR T. They are today’s “Hot Topics.” Is Europe playing its part? And is it creating “Hot Spots” of innovation to lead the way forward? And how Europe must keep pace to attract the best talent and investment, create jobs and improve public health? For its 20th anniversary, Bio€quity Europe begins with “Biotech in Europe: Scaling Innovation," an exclusive report from Insights Partner McKinsey & Co. Based on a survey of industry KOLs, this report will provide food for discussion on such key questions as:
• Are Europe’s biotech hotspots playing their part in global biotech innovation?
• The great European biotech funding evolution: Where next?
• How can CEOs and investors best play their cards in this context?

Session Chair:
• David Flores, President & CEO, BioCentury

Featuring:
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.

10:15  to  11:00
European Leaders Respond
Room - Rubí + Zafir (level -1)
Where Can Europe Lead?
A cross-section of entrepreneurs, researchers and investors debate the McKinsey findings and identify where Europe can create global impact in genetic and genomic medicine, novel modalities, next-generation manufacturing and digital healthcare.

Session Chair:
• Simone Fishburn, Ph.D., VP & Executive Editor, BioCentury

Featuring:
• Jeanne Bolger, M.D., VP, Venture Investments, Johnson & Johnson Development Corp.
• Roel Bulthuis, Managing Director, INKEF Capital
• Miriam Frieden, VP, Search & Evaluation, Novo Nordisk A/S
• Antoine Papiernik, Managing Partner & Chairman, Sofinnova Partners
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
• Jose Terencio, Ph.D., VP Innovation and R+D Coordination, Grifols Innovation and New Technologies
• Erica Whittaker, Ph.D., Head, UCB Ventures

11:00  to  11:15
Coffee Break and Presentation Room conversion
Crowne Plaza Barcelona Fira Center
11:15  to  12:00
Plenary 3
Room - Rossini 1 & 2
Creating Hot Topic Companies in Europe
Europe has held its own in the race to bring new modalities to the marketplace. Bio€quity’s globally facing VCs now identify where the next wave of leading edge start-ups can be created in Europe, and what they will have to do to attract finance in the global competition for capital.

Session Chair:
• Jan de Kerpel, Ph.D., Managing Director, Kempen & Co.

Featuring:
• Hakan Goker, Ph.D., Executive Investment Director, M Ventures B.V.
• John de Koning, Ph.D., Partner, LSP
• Jose Antonio Mesa, Life Sciences Managing Director, Caixa Capital Risc
• Søren Møller, Ph.D., Partner, Novo Holdings A/S
• Alan O'Connell, Ph.D., Partner, Seroba Life Science
• Jonathan Tobin, Ph.D., Investment Director, Arix Bioscience plc

Plenary 4
Room - Vivaldi 1 & 2
Creating Conditions for Hot Spots in Europe
Creating magnet zones for science, talent and capital requires policy, regulatory, legal and regional leadership. A cross-section of public and private sector stakeholders assess the environment for building and sustaining high-impact zones for the life sciences in Europe.

Session Chair:
• Gary Howes, Life Sciences Specialist, Lawyer, Senior Counsel, McDermott Will & Emery LLP

Featuring:
• Adelaide Cracco, Head of Life Sciences, European Investment Fund (EIF)
• Frank Kalkbrenner, M.D., Managing Director, Boehringer Ingelheim Venture Fund
• Graziano Seghezzi, Managing Partner, Sofinnova Partners
• Paul‐Peter Tak, M.D., Ph.D., President & CEO, Kintai Therapeutics Inc.
• Griet Vanpoucke, Ph.D., Head, New Ventures, VIB


12:00  to  13:45
Lunch
Crowne Plaza Barcelona Fira Center
13:30  to  14:45
CEO Workshop 9.0
Room - Rossini 1
C-Suite Management
Great science and technology eventually need great C-Suite leadership. When is it time to elevate or bring in C-Suite competence? How do you determine which C-Suite roles to fill from within and when is it time to go outside? And what characteristics and qualities make someone a C-suiter? BioEquity's 9th CEO Workshop will explore these topics from a CEO, board and investor perspective.

Session Chair:
• Carole Nuechterlein, Head, Roche Venture Fund

Featuring:
• Joël Jean‐Mairet, Ph.D., General Partner, Ysios Capital Partners
• Allan Marchington, Ph.D., Managing Partner, Bridge Valley Ventures
• Edwin Moses, Ph.D., Former CEO, Ablynx N.V.
• Sarah Shackelton, Partner, Marketing and Talent, Abingworth LLP

13:30  to  13:45
Presenting Company Sessions
Room - Rossini 2
eTheRNA immunotherapies N.V.
Presenting Company Sessions
Room - Vivaldi 2
EpimAb Biotherapeutics Inc.

13:30  to  13:40
Next Wave Sessions
Room - Vivaldi 1
Senti Biosciences Inc.
13:40  to  13:50
Next Wave Sessions
Room - Vivaldi 1
Confo Therapeutics N.V.
13:45  to  14:00
Presenting Company Sessions
Room - Rossini 2
ISA Pharmaceuticals B.V.
Presenting Company Sessions
Room - Vivaldi 2
Ability Pharmaceuticals S.L.

13:50  to  14:00
Next Wave Sessions
Room - Vivaldi 1
Amylon Therapeutics B.V.
14:00  to  14:15
Presenting Company Sessions
Room - Rossini 2
Mission Therapeutics Ltd.
Presenting Company Sessions
Room - Vivaldi 2
Asceneuron S.A.

14:00  to  14:10
Next Wave Sessions
Room - Vivaldi 1
LNC Therapeutics
14:10  to  14:20
Next Wave Sessions
Room - Vivaldi 1
Mimetas B.V.
14:15  to  14:30
Next Wave Sessions
Room - Rossini 2
Lykera Biomed S.A.
Presenting Company Sessions
Room - Vivaldi 2
Allecra Therapeutics S.A.

14:20  to  14:30
Next Wave Sessions
Room - Vivaldi 1
Beactica AB
14:30  to  14:45
Presenting Company Sessions
Room - Rossini 2
Cardior Pharmaceuticals GmbH
Presenting Company Sessions
Room - Vivaldi 2
IGEM Therapeutics Ltd.

14:30  to  14:40
Next Wave Sessions
Room - Vivaldi 1
Depixus S.A.S.
14:40  to  14:50
Next Wave Sessions
Room - Vivaldi 1
Motion Capture Group
14:45  to  15:00
Presenting Company Sessions
Room - Rossini 2
Laboratoris Sanifit S.L.
Presenting Company Sessions
Room - Vivaldi 2
Apeiron Biologics AG

14:50  to  15:00
Next Wave Sessions
Room - Vivaldi 1
Atriva Therapeutics GmbH
15:00  to  16:15
Regional Host Showcase
Room - Rossini 1
Scaling Up Catalonia
The number of international investors in the BioRegion of Catalonia has doubled in just 2 years. Biocat, the Regional Host of Bio€quity Europe, showcases companies that typify the untapped opportunity for investment in one of Europe’s fastest-growing life science hubs.

Session Chair:
• Jordi Naval, CEO, Biocat

Presenting companies:
• Allinky Biopharma S.L.
• Aniling S.L.
• GlyCardial Diagnostics S.L.
• IDP Pharma S.L.
• VCN Biosciences S.L.
• ZeClinics S.L.
15:00  to  15:15
Presenting Company Sessions
Room - Rossini 2
Topas Therapeutics GmbH
Presenting Company Sessions
Room - Vivaldi 2
Cantargia AB (SSE:CANTA)

15:00  to  15:10
Next Wave Sessions
Room - Vivaldi 1
Macrophage Pharma Ltd.
15:10  to  15:20
Next Wave Sessions
Room - Vivaldi1
Polyneuron Pharmaceuticals AG
15:15  to  15:30
Presenting Company Sessions
Room - Rossini 2
Minoryx Therapeutics S.L.
Presenting Company Sessions
Room - Vivaldi 2
Oryzon Genomics S.A. (Madrid:ORY)

15:20  to  15:30
Next Wave Sessions
Room - Vivaldi 1
AIMM Therapeutics B.V.
15:30  to  15:45
Presenting Company Sessions
Room - Rossini 2
Genkyotex S.A. (Euronext:GKTX)
Presenting Company Sessions
Room - Vivaldi 2
MC2 Therapeutics A/S

15:30  to  15:40
Next Wave Sessions
Room - Vivaldi 1
Secarna Pharmaceuticals GmbH
15:40  to  15:50
Next Wave Sessions
Room - Vivaldi 1
PDC*line Pharma S.A.S.
15:45  to  16:00
Presenting Company Sessions
Room - Rossini 2
Novadip Biosciences S.A.
Presenting Company Sessions
Room - Vivaldi 2
Pharvaris B.V.

15:50  to  16:00
Next Wave Sessions
Room - Vivaldi 1
iOnctura S.A.
16:00  to  16:15
Presenting Company Sessions
Room - Rossini 2
Aelix Therapeutics S.L.
Presenting Company Sessions
Room - Vivaldi 2
Cellestia Biotech AG

16:00  to  16:10
Next Wave Sessions
Room - Vivaldi 1
Rewind Therapeutics
16:10  to  16:20
Next Wave Sessions
Room - Vivaldi 1
AgomAb Therapeutics N.V.
16:15  to  16:30
Presenting Company Sessions
Room - Rossini 2
Vaxxilon AG
Presenting Company Sessions
Room - Vivaldi 2
M2RLABS

16:20  to  16:30
Next Wave Sessions
Room - Vivaldi1
Rejuvenate Biomed N.V.
16:30  to  17:45
China
Room - Rossini 1
An R&D Hot Spot for European Biotechs
China's regulatory reforms and its adoption of ICH standards have paved the way for Western innovators to extend their global R&D strategies to the second-largest pharma market. At the same time, European and Chinese interests are converging on many Hot Topics, including gene and cell therapies, genomics and digital science. This workshop, organized by BioCentury and BayHelix, examines how European biotechs should be thinking about China as a Hot Spot for accelerating global development.

Session Chair:
• Joshua Berlin, Executive Director, New Ventures, BioCentury

Featuring:
• Dominique Doyen, Director, Business Development, 4SC AG
• Simon Cook, Clinical Research Director, Celleron Therapeutics Ltd.
• Da LIU, Managing Director, CR‐CP Life Science Fund
• Todd Yancey, M.D., SVP, Global Medical Affairs & New Market Development, BeiGene Ltd.
• Dan Zhang, M.D., Chairman, Fountain Medical Development Ltd.

16:30  to  16:45
Presenting Company Sessions
Room - Rossini 2
Adrenomed AG
16:30  to  16:40
Next Wave Sessions
Room - Vivaldi 1
Curadigm
16:40  to  16:50
Next Wave Sessions
Room - Vivaldi 1
Artios Pharma Ltd.
16:45  to  17:00
Presenting Company Sessions
Room - Rossini 2
HalioDx S.A.S.
16:50  to  17:00
Next Wave Sessions
Room - Vivaldi 1
Complix N.V.
17:00  to  17:15
Presenting Company Sessions
Room - Rossini 2
Synaffix B.V.
17:00  to  17:10
Next Wave Sessions
Room - Vivaldi 1
ImCheck Therapeutics S.A.S.
17:15  to  17:30
Presenting Company Sessions
Room - Rossini 2
Immunic Inc. (NASDAQ:IMUX)
17:30  to  17:45
Presenting Company Sessions
Room - Rossini 2
Alkahest Inc.
18:30  to  19:00
Transportation to Networking Reception and Dinner
19:00  to  22:30
Networking Reception and Dinner
Palau Reial de Pedralbes - Avinguda Diagonal, 686, 08034 Barcelona
Tuesday, May 21, 2019

07:45  to  15:30
Registration Open
Crowne Plaza Barcelona Fira Center
07:45  to  09:00
Light Breakfast
Crowne Plaza Barcelona Fira Center
09:00  to  10:00
Workshop
Room - Rossini 1
Hot Topics; Hot Stocks
Euronext lays out the strategic value of raising capital on the public stock market -- including the ability to accelerate growth, boost a company's profile with stakeholders and provide liquidity for investors wanting buy or sell shares -- and shows how Euronext's TechShare pre-IPO program can help biotech companies take the next step. Including a Q&A session with Euronext executives.

Session Chair:
• Susana de Antonio, Director, Spain Representative, Euronext

09:00  to  09:15
Presenting Company Sessions
Room - Vivaldi 2
Achilles Therapeutics Ltd.
09:00  to  09:10
Next Wave Sessions
Room - Vivaldi 1
Storm Therapeutics Ltd.
09:10  to  09:20
Next Wave Sessions
Room - Vivaldi 1
Senolytic Therapeutics Inc.
09:15  to  09:30
Presenting Company Sessions
Room - Vivaldi 2
DCPrime B.V.
09:20  to  09:30
Next Wave Sessions
Room - Vivaldi 1
SNIPR Biome ApS
09:30  to  09:45
Presenting Company Sessions
Room - Vivaldi 2
NBE-Therapeutics AG
09:30  to  09:40
Next Wave Sessions
Room - Vivaldi 1
OxStem Ltd.
09:40  to  09:50
Next Wave Sessions
Room - Vivaldi 1
VarmX B.V.
09:45  to  10:00
Presenting Company Sessions
Room - Vivaldi 2
MiNA Therapeutics Ltd.
09:50  to  10:00
Next Wave Sessions
Room - Vivaldi 1
Aelin Therapeutics N.V.
10:00  to  11:00
Workshop
Room - Rossini 1
Drawing Your Financing Roadmap
Faced with an expanding range of financing options, early stage biotech executives must figure out how to navigate the pathway from seed through venture and public market rounds, while not missing non-dilutive money along the way. This workshop will review the early stage landscape -- such as financing from angels and family offices -- and debate how companies can best prepare for their next money raise.

Session Chair:
• Brian Coleman, Managing Director, Global Head of Financing & Sales, Locust Walk

Featuring:
• Clara Campàs, Ph.D., Partner, Asabys Partners
• Mark Epstein, Managing Partner, MTS Health Partners L.P.
• Arthur Franken, Partner, Gilde Healthcare
• Robert Habib, CEO, MiNA Therapeutics
• Caroline Saï, Operations Manager, Angels Santé & European Coordinator of the EIT Health Investor Network

10:00  to  10:15
Presenting Company Sessions
Room - Vivaldi 2
Promethera Biosciences S.A.
10:00  to  10:10
Next Wave Sessions
Room - Vivaldi 1
Virion Biotherapeutics Ltd.
10:10  to  10:20
Next Wave Sessions
Room - Vivaldi 1
GammaDelta Therapeutics Ltd.
10:15  to  10:30
Next Wave Sessions
Room - Vivaldi 2
BlueHaven Therapeutics
10:20  to  22:30
Next Wave Sessions
Room - Vivaldi 1
Algenex S.L.
10:30  to  10:45
Presenting Company Sessions
Room - Vivaldi 2
Numab Therapeutics AG
10:30  to  10:40
Next Wave Sessions
Room - Vivaldi 1
Calypso Biotech S.A.
10:40  to  10:50
Next Wave Sessions
Room - Vivaldi 1
Scenic Biotech B.V.
10:45  to  11:00
Presenting Company Sessions
Room - Vivaldi 2
Inivata Ltd.
11:00  to  12:00
Workshop
Room - Rossini 1
“Biotech in Europe: Scaling Innovation"
In a Q&A session, McKinsey & Co. partners provide details on the findings of their survey of European life science executives and investors.

Session Chair:
• Jorge Santos da Silva, Ph.D., Partner, McKinsey & Co.
11:00  to  11:15
Presenting Company Sessions
Room - Vivaldi 2
Xbrane Biopharma AB
11:15  to  11:30
Presenting Company Sessions
Room - Vivaldi 2
Vaximm AG
11:30  to  11:45
Presenting Company Sessions
Room - Vivaldi 2
IDIBELL
12:00  to  14:00
Grab & Go Lunch
Crowne Plaza Barcelona Fira Center
13:15  to  15:15
Pre-Seed Showcase
Room - Rossini 1
Selected Pre-Seed companies present to a diverse panel of Bio€quity Europe "judges," who provide high-level feedback on the entrepreneurs' presentations, business plans and overall strategy.

Session Chair:
• Eric Pierce, Publisher, BioCentury

Judges:
• Karen Bernstein, Ph.D., Co‐founder & Chairman, BioCentury
• Da LIU, Managing Director, CR‐CP Life Science Fund
• Vanessa Malier, Partner, Kurma Partners
• Alicia Irurzun-Lafitte, Partner, UCB Ventures

Presenting companies (Track 1): The companies presenting in this track are working on cancer and antimicrobial resistance
• (13:15) Remab Therapeutics
• (13:30) Ona Therapeutics S.L.
• (13:45) Valis Pharma
• (14:00) Nanoligent S.L.
• (14:15) AngioTheraGnostics
• (14:30) Cebiotix S.L.
• (14:45) Alderaan Biotechnology

Pre-Seed Showcase
Room - Vivaldi 1
Selected Pre-Seed companies present to a diverse panel of Bio€quity Europe "judges," who provide high-level feedback on the entrepreneurs' presentations, business plans and overall strategy.

Session Chair:
• Bernard V. Fallon, Managing Director, Industry Research & Education, Biotechnology Innovation Organization (BIO)

Judges:
• Peter Dudek, Partner, MRL Ventures Fund (MRLV)
• William Hariri, Director, Alira Health
• Lluís Pareras, M.D., Ph.D., Managing Partner, Invivo Ventures
• Ed Rayner, Investment Director, Arix Bioscience plc

Presenting companies (Track 2): The companies presenting in this track are working on gene therapies, lupus, CNS disorders and vaccines
• (13:15) PurPose Biotherapeutics
• (13:30) ADmit Therapeutics S.L.
• (13:45) Iproteos S.L.
• (14:00) VIB portfolio company
• (14:15) Gate2Brain
• (14:30) Avida Biotech
• (14:45) Biointaxis S.L.
• (15:00) MicrofluidX Ltd.


15:00  to  16:00
Closing Reception
Crowne Plaza Barcelona Fira Center
PRESENTERS

Presenting Company slots running out. Please email Eric Pierce to nominate your company.

Bio€quity Europe 2019 will be anchored by more than 80 investor-validated Presenting and Next Wave Companies. The financial community recognizes that the Presenting Companies are independently chosen by BioCentury based on rigorous criteria, including fundraising validation and upcoming milestones informed by the intelligence of the conference's leading sponsors.

 

  • Ability Pharma
  • Achilles Therapeutics
  • Adrenomed AG
  • Aelin Therapeutics
  • Aelix Therapeutics S.L.
  • AgomAb Therapeutics N.V.
  • Algenex S.L.
  • Alkahest Inc.
  • Allecra Therapeutics GmbH
  • Allinky Biopharma
  • Amylon Therapeutics B.V.
  • Aniling
  • Artios Pharma
  • Asceneuron S.A.
  • Atriva Therapeutics GmbH
  • Beactica AB
  • Bluehaven Therapeutics
  • Calypso Biotech B.V.
  • Cantargia AB
  • Cardior Pharmaceuticals GmbH
  • Cellestia Biotech AG
  • Complix N.V.
  • Confo Therapeutics N.V.
  • Curadigm
  • DCPrime B.V.
  • Depixus S.A.S.
  • EpimAb Biotherapeutics Inc.
  • eTheRNA immunotherapies N.V.
  • GammaDelta Therapeutics Ltd.
  • Genkyotex S.A.
  • Glycardial Diagnostics
  • HalioDx S.A.S.
  • Harbour BioMed
  • IDP Pharma
  • IDIBELL
  • ImCheck Therapeutics S.A.S.
  • Immunic Inc.
  • Inivata Ltd.
  • iOnctura S.A.
  • IGEM Therapeutics Ltd.
  • ISA Pharmaceuticals B.V.
  • Laboratoris Sanifit S.L.
  • LNC Therapeutics
  • Lykera BioMed S.A.
  • Macrophage Pharma Ltd
  • Mc2 Therapeutics As
  • Mimetas B.V.
  • MiNA Therapeutics
  • Minoryx Therapeutics
  • Mission Therapeutics Ltd.
  • Motion Capture Group GmbH
  • M2RLAB
  • NBE-Therapeutics AG
  • Novadip Biosciences
  • Numab Therapeutics AG
  • Oryzon Genomics S.A.
  • OxStem Ltd.
  • PDC*line Pharma
  • Pharvaris B.V.
  • Polyneuron Pharmaceuticals AG
  • Promethera Biosciences
  • Rejuvenate Biomed Nv
  • Rewind Therapeutics
  • Scenic Biotech B.V.
  • Secarna Pharmaceuticals GmbH
  • Senolytic Therapeutics Inc.
  • Senti Biosciences Inc.
  • SNIPR Biome ApS
  • Storm Therapeutics Ltd.
  • Synaffix B.V.
  • Topas Therapeutics
  • VarmX B.V.
  • Vaximm AG
  • Vaxxilon AG
  • VCN Biosciences
  • Virion Biotherapeutics Ltd.
  • Xbrane Biopharma Ab
  • ZeClinics
SPONSORS

ORGANIZERS

  • {title}
  • {title}

FOUNDING SPONSOR

  • {title}

INSIGHTS PARTNER

  • {title}

GOLD SPONSOR

  • {title}

SILVER SPONSORS

  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}

INTERNATIONAL HOST PARTNER

  • {title}

REGIONAL HOST COMMITTEE

  • {title}
  • {title}
  • {title}
  • {title}

REGIONAL HOST PLATINUM SPONSORS

  • {title}
  • {title}

REGIONAL HOST GOLD SPONSORS

  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}
  • {title}

SUPPORTING PARTNERS

  • {title}
  • {title}
  • {title}

FACULTY
Jaume Amat Riera

Jaume Amat Riera

Board Member
CataloniaBio & HealthTech
Joshua Berlin

Joshua Berlin

Executive Director, New Ventures
BioCentury
Karen Bernstein, Ph.D.

Karen Bernstein, Ph.D.

Chairman
BioCentury
Jeanne Bolger, M.D.

Jeanne Bolger, M.D.

Vice President, Venture Investments
Johnson & Johnson Development Corp.
Jasper Bos, Ph.D.

Jasper Bos, Ph.D.

Senior VP & Managing Director
M Ventures B.V.
Roel Bulthuis

Roel Bulthuis

Managing Director
INKEF Capital
Clara Campàs, Ph.D.

Clara Campàs, Ph.D.

Partner
Asabys Partners
José María Alonso Capelo

José María Alonso Capelo

Director, Deal Advisory Capital Markets
KPMG
Brian Coleman

Brian Coleman

Managing Director, Global Head of Financing & Sales
Locust Walk
Simon Cook

Simon Cook

Clinical Research Director
Celleron Therapeutics Ltd.
Adelaide Cracco

Adelaide Cracco

Head of Life Sciences
European Investment Fund
Jorge Santos da Silva, Ph.D.

Jorge Santos da Silva, Ph.D.

Partner
McKinsey & Company
Susana De Antonio

Susana De Antonio

Director, Spain Representative
Euronext
Fiona de Hemptinne

Fiona de Hemptinne

Partner
UCB Ventures
John de Koning, Ph.D.

John de Koning, Ph.D.

Partner
LSP
Jan de Kerpel, Ph.D.

Jan de Kerpel, Ph.D.

Managing Director
Kempen & Co.
Dominique Doyen

Dominique Doyen

Director, Business Development
4SC AG
Peter Dudek

Peter Dudek

Partner
MRL Ventures Fund (MRLV)
Mark Epstein

Mark Epstein

Managing Partner
MTS Health Partners L.P.
Bernard V. Fallon

Bernard V. Fallon

Managing Director, Industry Research & Education
Biotechnology Innovation Organization (BIO)
David Flores

David Flores

President & CEO
BioCentury
Simone Fishburn, Ph.D.

Simone Fishburn, Ph.D.

Vice President and Executive Editor
BioCentury
Arthur Franken

Arthur Franken

Partner
Gilde Healthcare
Miriam Frieden

Miriam Frieden

VP of Search & Evaluation
Novo Nordisk A/S
Hakan Goker, Ph.D.

Hakan Goker, Ph.D.

Executive Investment Director
M Ventures B.V. 
Keno Gutierrez, Ph.D.

Keno Gutierrez, Ph.D.

Investment Director
M Ventures B.V.
Robert Habib

Robert Habib

CEO
MiNA Therapeutics
William Hariri

William Hariri

Director
Alira Health
Rüdiger Herrmann, Ph.D.

Rüdiger Herrmann, Ph.D.

Partner
McDermott Will & Emery LLP
Gary Howes

Gary Howes

Life Sciences Specialist, Lawyer, Senior Counsel
McDermott Will & Emery LLP
Alicia Irurzun-Lafitte

Alicia Irurzun-Lafitte

Partner
UCB Ventures
Joël Jean-Mairet, Ph.D.

Joël Jean-Mairet, Ph.D.

General Partner
Ysios Capital Partners
Frank Kalkbrenner, M.D.

Frank Kalkbrenner, M.D.

Head
Boehringer Ingelheim Venture Fund
Emmanuel Lacroix, Ph.D.

Emmanuel Lacroix, Ph.D.

Partner
UCB Ventures
Nick La Thangue

Nick La Thangue

CEO
Celleron Therapeutics Ltd.
Da Liu

Da Liu

Managing Director
CR-CP Life Science Fund 
Vanessa Malier

Vanessa Malier

Managing Partner
Kurma Partners
Allan Marchington, Ph.D.

Allan Marchington, Ph.D.

Managing Partner
Bridge Valley Ventures
Jose Antonio Mesa

Jose Antonio Mesa

Life Sciences Managing Director
Caixa Capital Risc
Søren Møller, Ph.D.

Søren Møller, Ph.D.

Partner
Novo Holdings A/S
Edwin Moses, Ph.D.

Edwin Moses, Ph.D.

Former CEO
Ablynx N.V.
Jordi Naval

Jordi Naval

CEO
Biocat
Carole Nuechterlein

Carole Nuechterlein

Head
Roche Venture Fund
Alan O'Connell, Ph.D.

Alan O'Connell, Ph.D.

Partner
Seroba Life Sciences
Antoine Papiernik

Antoine Papiernik

Managing Partner & Chairman
Sofinnova Partners
Lluís Pareras, M.D., Ph.D.

Lluís Pareras, M.D., Ph.D.

Managing Partner
Invivo Ventures
Jacob Petersen

Jacob Petersen

Corporate VP, Head of Stem Cell R&D
Novo Nordisk A/S
Eric Pierce

Eric Pierce

Publisher
BioCentury
Edward Rayner

Edward Rayner

Investment Director
Arix Bioscience plc
Caroline Saï

Caroline Saï

Operations Manager, Angels Santé & European Coordinator
EIT Health Investor Network
Graziano Seghezzi

Graziano Seghezzi

Managing Partner
Sofinnova Partners
Sarah Shackelton

Sarah Shackelton

Partner, Marketing and Talent
Abingworth LLP
Paul-Peter Tak, M.D., Ph.D.

Paul-Peter Tak, M.D., Ph.D.

President & CEO
Kintai Therapeutics Inc.
Jose Terencio, Ph.D.

Jose Terencio, Ph.D.

VP Innovation and R+D Coordination
Grifols
Jonathan Tobin, Ph.D.

Jonathan Tobin, Ph.D.

Investment Director
Arix Bioscience plc
Griet Vanpoucke, Ph.D.

Griet Vanpoucke, Ph.D.

Head, New Ventures
VIB
Erica Whittaker, Ph.D.

Erica Whittaker, Ph.D.

Head
UCB Ventures
Todd Yancey, M.D.

Todd Yancey, M.D.

SVP, Global Medical Affairs & New Market Development
BeiGene Ltd.
Dan Zhang, M.D.

Dan Zhang, M.D.

Chairman
Fountain Medical Development Ltd.